Secukinumab is a Monoclonal Antibody owned by Novartis, and is involved in 159 clinical trials, of which 116 were completed, 38 are ongoing, and 5 are planned.
Secukinumab (AIN457) selectively neutralizes interleukin-17A. Interleukin-17A is a key pro-inflammatory cytokine expressed by TH17 cells. Interleukin-17A (IL-17A) is a CD4+ T cell-derived cytokine that promotes inflammatory responses and is elevated in rheumatoid arthritis (RA), asthma, multiple sclerosis, psoriasis, and transplant rejection. So neutralizing effect of the drug on IL-17A helps in treating autoimmune disorders. IL-17A does not play a role in physiological bone remodelling. IL-17A is secreted by Th17 cells under inflammatory conditions. IL-17A upregulates RANK in osteoclast precursors, sensitizing them to RANKL-induced bone resorption. IL-17A is a suitable target to combat bone loss in inflammatory arthritis and autoimmune diseases such as RA.
The revenue for Secukinumab is expected to reach a total of $101.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Secukinumab NPV Report.
Secukinumab is originated and owned by Novartis.
Secukinumab (Cosentyx, Zafrez, Fraizeron) is an immunosuppressive agent. It is formulated as freeze-dried preparation for powder for solution and solution in prefilled syringe or pre-filled pen for subcutaneous route of administration. Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy; adult patients with active psoriatic arthritis and with active ankylosing spondylitis. It is also indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nraxSpA) with objective signs of inflammation and also indicated for the treatment of psoriasis vulgaris, psoriatic arthritis, and pustular psoriasis in children. Cosentyx (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. It is also indicated for the treatment for tendon injury.
Secukinumab is under development for the treatment of pyoderma gangrenosum, patients with active peripheral spondyloarthritis (pSpA), psoriasis, Necrobiosis Lipoidica Diabeticorum, non-radiographic axial spondyloarthritis, hidradenitis suppurativa, giant cell arteritis, atopic dermatitis and ichthyosis, lichen planus, lupus nephritis, non-alcoholic fatty liver disease. The drug candidate was under development for the treatment of atopic dermatitis, alopecia areata, contact dermatitis, moderate-to-severe plaque psoriasis in pediatrics, rheumatoid arthritis, bronchial asthma, non-infectious uveitis in patients with Behcet’s disease, neutrophilia, dry eye syndrome, thyroid eye disease (Graves ophthalmopathy), type 1 diabetes, severe Crohn's disease and relapsing-remitting multiple sclerosis (RRMS), chronic cutaneous lupus erythematosus, relapsing multiple sclerosis and severe acute respiratory syndrome (SARS) associated with Covid-19 and Covid-19 associated pneumonia.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – Secukinumab
|Highest Development Stage|